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CysteamineCystamine and its reduced form cysteamine showed protective effects in various models of neurodegenerative
disease, including Huntington's disease and Parkinson's disease. Other lines of evidence demonstrated the cyto-
toxic effect of cysteamine on duodenal mucosa leading to ulcer development. However, the mechanism for cys-
tamine cytotoxicity remains poorly understood. Here, we report a new pathway in which cystamine induces
apoptosis by targeting apoptosis-inducing factor (AIF). By screening of various cell lines, we observed that cysta-
mine and cysteamine induce cell death in a cell type-speciﬁc manner. Comparison between cystamine-sensitive
and cystamine-resistant cell lines revealed that cystamine cytotoxicity is not associatedwith unfolded protein re-
sponse, reactive oxygen species generation and transglutaminase or caspase activity; rather, it is associated with
the ability of cystamine to trigger AIF nuclear translocation. In cystamine-sensitive cells, cystamine suppresses
the levels of intracellular glutathione by inhibiting γ-glutamylcysteine synthetase expression that triggers AIF
translocation. Conversely, glutathione supplementation completely prevents cystamine-induced AIF transloca-
tion and apoptosis. In rats, cysteamine administration induces glutathione depletion and AIF translocation lead-
ing to apoptosis of duodenal epithelium. These results indicate that AIF translocation through glutathione
depletion is the molecular mechanism of cystamine toxicity, and provide important implications for cystamine
in the neurodegenerative disease therapeutics as well as in the regulation of AIF-mediated cell death.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Cystamine is a disulﬁde amine that has antioxidative capacity and al-
ters cellular antioxidant system [1–3]. Under intracellular conditions,
cystamine is in equilibrium with its reduced form cysteamine which
has a direct antioxidant effect [4–6]. In neuronal tissue, cystaminebiotinamidopentylamine; BSA,
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4534.protected against cell death in several disease models that are thought
to be associated with oxidative stress, including Huntington's disease
[7,8], Parkinson's disease [9,10], dentatorubral-pallidoluysian atrophy
[11] and neuropsychiatric systemic lupus erythematosus [12]. Thus,
therapeutic effect of cysteamine for patients with Huntington's disease
has been tested in clinical trial [13]. In addition to the role of cystamine
as an antioxidant, other mechanisms have been proposed for its
neuroprotective effect. It has been shown that cystamine modulates
the apoptotic process by inhibition of enzymes such as caspase-3 and
transglutaminases [3,5,14]. Moreover, cystamine is also involved in
the regulation of cellular responsiveness to oxidative stress. It has
been reported that cystamine increases the expression levels of heat-
shock protein [8], brain-derived neurotrophic factor [15] and glutathi-
one transferase A3 [16]. These observations indicate that cystamine di-
rectly or indirectly suppresses oxidative stress-induced neuronal cell
death.
However, other lines of evidence demonstrated that cystamine
promotes oxidative stress-induced cell death in other type of cells, espe-
cially in intestinal epithelium, by inhibition of γ-glutamylcysteine
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Cystamine is known to inhibit GCS through a sulfhydryl–disulﬁde inter-
change reaction between sulfhydryl groups at or around the active site
of the GCS and cystamine [6], and the reduced form cysteamine also
acts as a competitive inhibitor [5]. Indeed, Vanin-1, a cysteamine
synthesizing enzyme, deﬁcient mice showed no detectable free
cysteamine and increased levels of intracellular GSH in intestinal epi-
thelium [18,19]. Consequently, these mice were resistant to oxidative
stress and inﬂammation, and deﬁcient phenotypes were reversed by
cystamine administration [6,19]. Moreover, cysteamine administration
induces cell death of duodenal mucosal cells [20], possibly by generating
hydrogen peroxides [19], resulting in perforating ulcers in rat. This rat
model of cysteamine-induced duodenal ulcer is easily reproducible and
similar to human duodenal ulcer, and thus has been used for studying
the pathogenesis of duodenal ulceration. The concentration of cysteamine
used in rat duodenal ulcer model (intragastric, 250 mg/kg three times at
4 h intervals) was similar to the concentration of cystamine in mouse
neurodegenerative disease models (intraperitoneally, 100–750 mg/kg)
[7,9,20]. These observations indicate that the effect of cystamine on cell
survival is partly dependent on cell-type, and that investigation on the
mechanism for cystamine cytotoxicity is needed for re-evaluating cysta-
mine as a new medication for neurodegenerative diseases as well as for
better understanding of the etiology of duodenal ulceration.
GSH is themost important non-protein antioxidant and has a critical
role in maintaining cellular redox status. Under physiological condi-
tions, intracellular GSH concentrations range from 1 to 11 mM. Al-
though GCS expression and activity is tightly regulated at different
levels tomaintain GSH concentration [21], GSH is depleted by increased
oxidative stress or treatmentwith apoptotic agents such as death recep-
tor ligands or chemotherapeutics [22]. Thus, the level of intracellular
GSH is considered to be a marker for cellular redox status during oxida-
tive stress-induced cell death. However, it is also known that GSHdeple-
tion per se induces cell death. GCS deﬁcient mice displayed embryonic
lethality due to a massive cell death [23]. Pharmacological inhibition
of GCS with buthionine sulfoximine (BSO) induces or stimulates cell
death [24,25]. Moreover, GSH depletion is required for Fas ligand-
induced apoptosis regardless of reactive oxygen species (ROS) genera-
tion and oxidative stress [26], suggesting a previously unidentiﬁed
mechanism for oxidative stress-induced cell death.
Apoptosis-inducing factor (AIF) is a ﬂavoprotein that is located in
the mitochondrial intermembrane space and plays major roles in
mediating caspase-independent cell death [27]. Upon cell death stimuli,
AIF is cleaved within the mitochondria by calpains and cathepsins [28],
released into cytosol possibly through a mitochondrial permeability
transition pore, and translocated into the nucleus where it induces
chromatin condensation and DNA fragmentation through complex for-
mation with H2AX and cyclophilin A [29,30]. A number of apoptotic
stimuli have been documented to induce AIF mitochondria-to-nucleus
translocation including DNA damaging agents, hypoxia/ischemia, oxi-
dative stress and excitotoxins such as glutamate [27]. However, the sig-
nalingpathways that causeAIF nuclear translocation have not been fully
elucidated.
In this study, we examined the cystamine cytotoxicity in various
tumor cell lines, and found that cystamine induces caspase-
independent cell death in a cell-type speciﬁc manner. In cystamine-
sensitive cell lines, cystamine causes the depletion of intracellular GSH
which triggers AIF nuclear translocation. These results were veriﬁed in
a rat model of cysteamine-induced duodenal ulcer.
2. Materials and methods
2.1. Cell culture
DU145, human prostate cancer cells and HeLa, human cervical
cancer cells were maintained in Dulbecco's modiﬁed Eagle medium
(WelGENE, Daegu, Korea) containing 10% heat-inactivated fetal bovineserum (Hyclone, Logan, UT, USA). The neuroblastoma cells, SK-N-SH
and SH-SY-5Ywere also cultured in Dulbecco's modiﬁed Eaglemedium.
MCF7, human breast cancer cells and A549, human lung cancer cells
were maintained in RPMI 1640 medium (WelGENE) containing 10%
heat-inactivated fetal bovine serum. Penicillin (100 U/ml; Invitrogen,
Carlsbad, CA, USA), streptomycin sulfate (100 μg/ml; Invitrogen) and
glutamine (2 mM; Invitrogen) were supplemented to all cell culture
media. All cells were maintained in a humidiﬁed incubator with 5%
CO2 at 37 °C.
All cells were grown to 20% conﬂuence and then treated with
cystamine, cysteamine, dithiothreitol (DTT; ICN Biomedicals Inc.,
Aurora, OH, USA) or β-mercaptoethanol (β-ME; Merck, Darmstadt,
Germany) for 72 h. Parallel groups of cells were pretreated with
N-acetylcysteine (NAC), vitamin C, vitamin E, Trolox (6-hydroxy-
2,5,7,8-tetramethylchroman-2-carboxylic acid), quercetin, glutathione
ethyl ester (GSH-EE), BSO or z-VAD-fmk for 1 h prior to addition of cys-
tamine or cysteamine. Cells were pretreated with polyethylene glycol
(PEG)-conjugated catalase for 4 h. All chemicals were purchased from
Sigma-Aldrich Corporation (St. Louis, MO, USA) unless otherwise
indicated.
HeLa cell lines expressing shRNA of transglutaminase 2 (TG2;
HeLashTG2) were established by transfection with pSUPER plasmid con-
taining shRNA for TG2 as described previously [31]. For knock-down of
AIF, HeLa cells were transfected with siRNA for AIF (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) using Lipofectamine 2000 (Invitrogen) ac-
cording to the manufacturer's instructions. The expression of TG2 and
AIF was conﬁrmed by Western blot analysis.
2.2. MTT colorimetric assay
Cells were cultured to 20% conﬂuence on 24-well dishes and treated
with cystamine, cysteamine, DTT or β-ME for the indicated times. After
washing with phosphate buffered saline (PBS), cells were incubated
for 4 h in MTT solution (500 μg/ml of tetrazolium MTT (3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich
Corporation) in culture medium). MTT solution was removed, and
dimethyl sulfoxide (DMSO) was added to dissolve the formazan crys-
tals. The 24-well dishes were slightly vortexed and incubated in the
dark. Samples were diluted to proper concentration and transferred to
a 96-well plate. The absorbance at 570 nm in each well was measured
by a microplate spectrophotometer. Values for untreated controls
were set at 100% cell viability, and each treatment was assessed as a
percentage of the control values. Each treatment was performed in
triplicate.
2.3. Lactate dehydrogenase release assay
Lactate dehydrogenase (LDH) released to culture medium was esti-
mated using CytoTox 96 Non-radioactive Cytotoxicity Assay (Promega,
Madison, WI, USA) according to the manufacturer's instruction. Cells
were treatedwith cystamine or cysteamine for 72 h, and 50 μl of culture
media was transferred to the 96-well plate. After the addition of 50 μl of
LDH substrate reagent to each well, the plate was incubated for 30 min
in the dark and 50 μl of stop solution was added. The absorbance at
490 nmwasmeasured by themicroplate spectrophotometer. The back-
ground values were subtracted, and each treatment was assessed as a
percentage of the untreated control values. Each treatment was per-
formed in triplicate.
2.4. In situ transglutaminase (TG) activity assay
Cells were incubated for 1 h with 1 mM 5-biotinamidopentylamine
(BP; Pierce, Rockford, IL, USA) and harvested by centrifugation. The
cells were ruptured by sonication, followed by centrifugation
(14000 g, 10 min at 4 °C). The cellular proteins (10 μg/well) in coating
buffer (50 mM Tris–Cl, pH 7.5, 150 mM NaCl, 5 mM EGTA, 5 mM
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activity was estimated by measuring the amount of BP that is incorpo-
rated into the proteins. The BP-incorporated products were probed
using horseradish peroxidase-conjugated streptavidin (Zymed Labora-
tories, South San Francisco, CA, USA) followed by a reaction with
o-phenylenediamine dihydrochloride (Sigma-Aldrich Corporation).
After incubation for 5 to 10 min at room temperature, the reaction
was stopped by the addition of H2SO4. The absorbance at 490 nm was
measured by the microplate spectrophotometer.
2.5. ROS detection using dichloroﬂuorescein (DCF)
For measurement of the ROS generation, cells were harvested by
centrifugation and incubated with 40 μM DCF in KRH buffer (10 mM
HEPES, pH 7.4, 150 mM NaCl, 6 mM KCl, 1 mM MgCl2) containing 0.2%
bovine serum albumin (BSA) and 1 μg/μl glucose for 30 min at 37 °C.
After washing, cells were then analyzed by ﬂow cytometry (Becton
Dickinson, San Jose, CA, USA)with 488 nm excitation and 535 nm emis-
sion ﬁlters. Data analysis was performed using the ModFit LT V3.0 soft-
ware (Verity Software House, Topsham, ME, USA).
2.6. Analysis of cellular DNA content by PI staining
Cellswere treatedwith 500 μMcystamine for 72h andwere harvest-
ed by trypsinization. Afterwashingwith PBS, cells (~1 × 106)were ﬁxed
in 1ml of 70% ethanol at 4 °C for overnight and resuspended in 200 μl of
PBS containing 50 μg/ml propidium iodide and 100 μg/ml RNase A. After
incubating for 30 min in the dark at room temperature, cells were then
analyzed by ﬂow cytometry (Becton Dickinson)with 488 nm excitation
and 610 nm emission ﬁlters.
2.7. Mitochondrial membrane potential
Mitochondriamembrane potentialwas evaluated using the lipophil-
ic cationic probe JC-1 (Invitrogen) according to the manufacturer's in-
struction. Cells were harvested and resuspended in PBS. After adding
2 μM JC-1, cells were incubated for 30 min at 37 °C with rotation. Cells
were washed with PBS and analyzed by ﬂow cytometry (Becton
Dickinson) using 488 nm excitation with emission ﬁlters appropriate
for 515 nm and 580 nm.
2.8. Confocal microscopy
After being treatedwith cystamine or cysteamine for 72 h, cells were
washedwith cold PBS. The cellswereﬁxedwith 4% formaldehyde in PBS
for 15 min at room temperature, and then permeabilized with 0.1% Tri-
ton X-100 in PBS for 5 min at room temperature followed by blocking
with 1% BSA in PBST (PBS containing 0.1% Tween-20) for 30 min. AIF
was labeled by an anti-AIF antibody (Santa Cruz Biotechnology) diluted
in PBST and ﬂuorescently labeled by 20 μg/ml of FITC-conjugated goat
anti-mouse IgG (Molecular Probes, Eugene, OR, USA) in PBS containing
1% BSA for 1 h. Nucleus was labeled by 1 μg/ml of DAPI (Roche, Mann-
heim, Germany) in the solution. A confocal ﬂuorescence microscope
(LSM 510 META; Carl Zeiss, Oberkochen, Germany) was used to visual-
ize the each sample.
2.9. Caspase-3-like and caspase-9-like activity assay
Caspase activitywasmeasured by using chromogenic substrates, Ac-
DEVD-pNA for caspase-3-like activity and Ac-LEHD-pNA for caspase-9-
like activity (A.G. Scientiﬁc Inc., San Diego, CA, USA), as previously de-
scribed with minor modiﬁcation [32]. Cells were harvested and lysed
in buffer (50 mM HEPES, pH 7.4, 0.1% CHAPS, 1 mM DTT, 0.1 mM
EDTA and 0.1% Triton X-100) for 30 min followed by centrifugation at
12000 g for 10min at 4 °C. The protein concentration in the supernatant
was quantitated by the BCA method (Pierce). The cell extract (50 μg ofprotein) was added to assay buffer (100 mM HEPES, pH 7.4, 0.1%
CHAPS, 10 mM DTT, 10% glycerol and 2% (v/v) DMSO) containing
2 mM chromogenic substrates and incubated for 4 h at 37 °C. Caspase
activity was quantiﬁed by measuring the absorbance at 405 nm on mi-
croplate spectrophotometer. Caspase activity is calculated as described
in the protocol for the CaspACE™ Assay System Kit (Promega) and
each treatment was assessed as a percentage of the untreated control
values.
2.10. Western blot analysis
Cells were sonicated in buffer (50mMTris–Cl, pH 7.4, 150mMNaCl,
1% Triton X-100, protease inhibitor cocktail (Roche) and phosphatase
inhibitor cocktail (Roche)) and centrifuged 20000 g for 10 min at 4 °C.
After determination of protein concentration in the cell extract by the
BCA method, 40 μg of protein was resolved by SDS-PAGE and trans-
ferred to a nitrocellulose membrane. Membranes were blocked for 1 h
with 5% skim milk in Tris-buffered saline, and incubated with anti-
TG2 [33], anti-AIF (Santa Cruz Biotechnology), anti-GCSC (catalytic sub-
unit of GCS; Santa Cruz Biotechnology) and anti-Actin (Sigma-Aldrich
Corporation) antibodies. The membranes were washed and incubated
with horseradish peroxidase-conjugated secondary antibody, followed
by enhanced chemiluminescence development according to the
manufacturer's instruction (Pierce).
2.11. Measurement of glutathione concentration
GSH concentration was estimated by using a GSH assay kit (Cayman
Chemical Co., Ann Arbor, MI, USA). Brieﬂy, cells and tissues were lysed
in buffer (50 mM Tris–Cl, pH 7.4, 150 mM NaCl, 1% Triton X-100),
and centrifuged 10000 g for 15 min. After determination of protein
concentration by the BCA method, cell lysates were subjected to se-
quential treatment of 5% (w/v) metaphosphoric acid (Sigma-Aldrich
Corporation) and 0.1 M triethanolamine (Sigma-Aldrich Corporation).
Deproteinized samples were mixed with a solution containing 5,5′-
dithio-bis-2-nitrobenzoic acid (DTNB), and 5-thio-2-nitrobenzoic acid
(TNB) produced by a reaction between the sulfhydryl groups of
GSH and DTNB was estimated by measuring absorbance at 405 or
412 nm. Total GSH and oxidized GSH concentrations were determined
after treatment of the samples with GSH reductase and 10 mM
2-vinylpyridine (Sigma-Aldrich Corporation), respectively. Reduced
GSH was calculated by subtraction of oxidized GSH from total GSH.
2.12. Duodenal ulcer model in rat
All animal procedures were approved by the Institutional Animal
Care and Use Committee at the Seoul National University College of
Medicine (IACUC Approval No. SNU-130624-1). Duodenal ulcers were
induced in female Sprague–Dawley rats aged 6–8 weeks (Orient,
Seoul, Korea) by intragastric administration of cysteamine as previously
reported [34]. Cysteamine (25 mg/100 g body weight, Sigma-Aldrich
Corporation) was given three times at 4 h intervals. Rats were eutha-
nized at 10 or 24 h after the ﬁrst dose of cysteamine and duodenums
were collected for estimation of GSH content and immunoﬂuorescence
staining.
2.13. Statistical analysis
All statistical calculations were performed using Prism 4.0
(GraphPad, San Diego, CA, USA). Differences between two variables
and multiple variables were assessed by unpaired Student's t test and
one-way ANOVA with Tukey's multiple comparison test, respectively.
The difference was considered signiﬁcant if the p value was less than
0.05.
622 S.-Y. Cho et al. / Biochimica et Biophysica Acta 1853 (2015) 619–6313. Results
3.1. Cystamine and cysteamine induce tumor cell-type speciﬁc cell death
To evaluate cystamine toxicity, we treated the DU145, HeLa, MCF7
and A549 cell lines with various cystamine concentrations for 72 h.
Interestingly, we discovered that cystamine treatment resulted in a
dose- and time-dependent cytotoxicity in the DU145 and HeLa cell
lines but showed no effect in the MCF7 and A549 cell lines (Fig. 1a–d).
In addition, neuroblastoma cells (SK-N-SH and SH-SY-5Y) were also re-
sistant to cystamine treatment (Fig. 1e). Cystamine is reduced into two
cysteamine molecules in the cytosol. To determine whether the cyto-
toxicity was caused by cystamine or its reduced form cysteamine, weFig. 1. Cell-type speciﬁc cystamine cytotoxicity. (a–d)DU145 (a), HeLa (b), MCF7 (c) and A549 (
monitored for 72h using anMTT assay. (e)Neuroblastoma cells (SK-N-SH and SH-SY-5Y)were t
were treated with cystamine or cysteamine for 72 h. Cell viability was measured by MTT assay
based on experiments that were performed in triplicate.also evaluated cysteamine toxicity in DU145 cells. Both MTT and LDH
release assays demonstrated that cysteamine also induced cell death
in a dose-dependent manner, and half of the cystamine dose was re-
quired to induce a similar rate of cell death compared to cysteamine-
treated cells (Fig. 1f, g), indicating that cysteamine is responsible for
cell type-speciﬁc cytotoxicity.
3.2. Cystamine cytotoxicity is not associated with unfolded protein
response, ROS generation or TG2 activity
We investigated the mechanisms for cystamine cytotoxicity.
Cysteamine is a reducing agent that could induce cell death by eliciting
unfolded protein response [35]. To test this possibility, we examined thed) cells were treatedwith various cystamine concentrations (0–500 μM). Cell viability was
reatedwith cystamine for 72h. Cell viabilitywasmeasured byMTT assay. (f, g)DU145 cells
(e) and LDH release assay (f). The data represent the mean values ± standard deviations
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ence in cell viability among the cystamine-sensitive and -resistant cells
(Fig. 2a, b), indicating that cystamine cytotoxicity is not caused by un-
folded protein response.
Cysteamine produces H2O2 by reaction of the thiol groupwithmetal
ions [36]. To assess this possibility, we measured ROS levels in DU145
cells using DCF dye. Cystamine or cysteamine treatment reduced, rather
than increased, ﬂuorescence intensity (Fig. 2c). Antioxidants such as vi-
tamin C, vitamin E, Trolox and quercetin had no effect on cystamineFig. 2.Cystamine-induced cell death is not associatedwith unfolded protein response, ROS gener
treated with dithiothreitol (0–5 mM, a) or β-mercaptoethanol (0–5 mM, b) for 72 h, and cell
(500 μM)or cysteamine (1000 μM) in the presence of N-acetylcysteine (NAC, 500 μM) for 72 h.
dye DCF. The graph represents themean values. (d) DU145 cells were treatedwith cystamine (5
200 μM), Trolox (Trol; 1 mM) or quercetin (Que; 10 μM). Cell viability was assessed by anMTT
polyethylene glycol (PEG)-conjugated catalase (PEG-cat; 500 U/ml). Cell viability was assessed
PEG-conjugated catalase. (f) TG2 protein levels and in situ TG activity in DU145, HeLa, MCF7 an
corporation assay, respectively. (g) HeLa cells were transfected with either shTG2 expression v
(0–500 μM) treatment for 72 h using anMTT assay. The protein levels of TG2 and actin were de
ations based on experiments that were performed in triplicate.toxicity. Interestingly, only NAC abrogated cystamine toxicity (Fig. 2d).
Moreover, exogenous H2O2 was more toxic to MCF7 and A549 cells
than DU145 andHeLa cells (data not shown), and addition of polyethyl-
ene glycol (PEG)-conjugated catalase had little effect on cystamine sen-
sitivity (Fig. 2e), suggesting that H2O2 generation did not contribute to
cystamine cytotoxicity.
TG2 suppresses oxidative stress-induced apoptosis through cross-
linking of caspase-3 and IκB [37], and cystamine inhibits TG2 by a
thiol–disulﬁde exchange reaction [36]. To test whether TG2 mightation and transglutaminase 2 (TG2) activity. (a, b) DU145, HeLa,MCF7 andA549 cellswere
viability was examined using an MTT assay. (c) DU145 cells were treated with cystamine
Cellular ROS levelswere estimated by ﬂow cytometry using the ROS-sensitive ﬂuorescence
00 μM) for 72 h in the presence of NAC (2mM), vitamin C (Vit C; 2mM), vitamin E (Vit E;
assay. (e) DU145 cells were treatedwith cystamine (0–500 μM) for 72 h in the presence of
by anMTT assay. H2O2 (1mM)-treated cells were used as positive controls for the effect of
d A549 cells was measured byWestern blot analysis and a 5-biotinamidopentylamine in-
ector (HeLashTG2) or control vector (HeLashGFP). Cell viability was assessed after cystamine
termined byWestern blot analysis. The data represent the mean values ± standard devi-
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its intracellular activity among cell lines. TG2 expression levels were
variable and not correlated with cystamine sensitivity (Fig. 2f). In situ
TG activity in DU145 and HeLa cells was higher than that in MCF7 and
A549 cells (Fig. 2f), and down-regulation of TG2 by shRNA in HeLa
cells had no effects on cystamine sensitivity (Fig. 2g). These results indi-
cate that cystamine cytotoxicity was not due to TG2 activity inhibition.
3.3. Cystamine-induced cell death depends on intracellular GSH levels
Cystamine treatment decreases cellular GSH level through GCS inhi-
bition [2,19]. We therefore speculated that cell-type speciﬁc cystamine-
induced cell death may be explained by a difference in the ability of the
cells to synthesize GSH. To test this hypothesis, we monitored GSHFig. 3. Cystamine depletes intracellular glutathione levels in a cell-type speciﬁc manner. (a, b)
reduced (b) GSH levels were monitored for 72 h. The GSH levels were expressed as a percent
deviations based on experiments that were performed in triplicate. (c, d) γ-Glutamylcysteine
byWestern blot analysis in cystamine-sensitive cells (DU145 and HeLa, c) and cystamine-resist
tamine-resistant cells (MCF7 and A549, f) were treatedwith glutathione ethyl ester (GSH-EE, 2
tamine (500 μM) treatment was monitored by MTT assay. The data represent the mean values
indicate statistically signiﬁcant differences (**p b 0.01) according to GSH-EE or BSO treatment.levels. Upon cystamine treatment, total and reduced GSH levels in
cystamine-sensitive cells (DU145 and HeLa) were maintained for 24 h
but decreased thereafter. In contrast, GSH levels in cystamine-resistant
cells (MCF7 and A549) were increased approximately 1.8- to 2.2-fold
after 24 h, and basal GSH levels were maintained even in the presence
of cystamine (Fig. 3a, b), demonstrating that GSH levels are well corre-
latedwith cystamine susceptibility.We next assessedwhether GCS pro-
tein levels are important in regulating intracellular GSH levels. Western
blot analysis revealed that in cystamine-sensitive cells, GCS levels were
increased during the initial 24 h of cystamine treatment, but decreased
abruptly after 48 or 72 h (Fig. 3c), whereas in cystamine-resistant cells,
basal GCS levels were maintained for 72 h (Fig. 3d), indicating that GCS
expression is correlatedwith intracellular GSH levels and amajor deter-
minant of cystamine sensitivity.DU145, HeLa, MCF7 and A549 cells were treated with cystamine (500 μM). Total (a) and
age of untreated control in each cell line. The data represent the mean values ± standard
synthetase catalytic subunit (GCSC) expression was evaluated after cystamine treatment
ant cells (MCF7 and A549, d). (e, f) Cystamine-sensitive cells (DU145 and HeLa, e) and cys-
.5mM, e) and buthionine sulfoximine (BSO, 200 μM, f), respectively. Cell viability after cys-
± standard deviations based on experiments that were performed in triplicate. Asterisks
625S.-Y. Cho et al. / Biochimica et Biophysica Acta 1853 (2015) 619–631We asked whether augmenting intracellular GSH levels could pre-
vent cystamine-induced cell death. In cystamine-treated DU145 and
HeLa cells, GSH-EE supplementation completely rescued cystamine-
induced cell death (Fig. 3e). Conversely, GSH synthesis inhibition by
BSO treatment rendered MCF7 and A549 cells cystamine-sensitive
(Fig. 3f), demonstrating that GSH depletion is critical for triggering cell
death.Fig. 4. Cystamine treatment induces caspase-independent apoptosis. (a) Representative exampl
cells after 72 h of treatment. Cells were stained with propidium iodide. M1 represents the perce
(500 μM)or cysteamine (1000 μM)-treatedHeLa cells in the presence of NAC (500 μM). Scale ba
Mitochondrial membrane potential was analyzed by ﬂow cytometry using JC-1 dye. The numb
(d) Caspase-3-like and -9-like activities were measured after cystamine (200 and 500 μM) tre
and -9-like activities after ultraviolet (UV) irradiation were used as positive controls. (e) Ce
(10 μM) was assessed using an MTT assay. The data represent the mean values ± standard de3.4. Cystamine induces caspase-independent cell death
To gain insight into the mechanisms of cystamine cytotoxicity,
we investigated the morphological and biochemical features of
cystamine-induced cell death [38].Weexamined the effect of cystamine
on DNA fragmentation by staining with propidium iodide. Flow
cytometric analysis revealed that cystamine treatment resulted ines of ﬂow cytometry proﬁles from cystamine (500 μM) and/or NAC (500 μM)-treatedHeLa
ntage of cells containing sub-G1 DNA content. (b) Representative DAPI-stained cystamine
r: 50 μm. (c) Cellswere treatedwith cystamine (500 μM)or cysteamine (1000 μM) for 72h.
er in each graph indicates the relative percentage of cells with reduced red ﬂuorescence.
atment using Ac-DEVD-pNA and Ac-LEHD-pNA as substrates, respectively. Caspase-3-like
ll viability after cystamine (500 μM) treatment for 72 h in the presence of z-VAD-fmk
viations based on experiments that were performed in triplicate.
626 S.-Y. Cho et al. / Biochimica et Biophysica Acta 1853 (2015) 619–631approximately a 3-fold increase of the SubG1 fraction in DU145 cells
compared with control cells (Fig. 4a). When stained with DAPI,
cystamine- or cysteamine-treated cells displayed condensed chromatin
compared with control cells (Fig. 4b). Moreover, cystamine or cyste-
amine evoked mitochondrial membrane depolarization (Fig. 4c).
These features were prevented by NAC (Fig. 4a–c). However, when cas-
pase-3-like and -9-like activities were measured, we found no increase
in either caspase activity in cystamine-treated cells (Fig. 4d). Further-
more, the caspase inhibitor z-VAD-fmk did not affect cystamine
cytotoxicity (Fig. 4e), implying that cystamine-induced cell death is in-
dependent of caspase activity.Fig. 5.Cystamine treatment triggers nuclear translocation of apoptosis-inducing factor (AIF). (a)
with cystamine (500 μM) for 72 h and immunostained with anti-AIF antibodies and FITC-conju
copywith DAPI staining. Scale bar: 50 μm. (b) DU145 cells were immunostainedwith anti-AIF a
or NAC (500 μM). Scale bar: 50 μm. (c) Effect of AIF-knockdown on cystamine-induced cell deat
cystamine treatment for 72 hweremeasured byWestern blot analysis andMTT assay, respectiv
were performed in triplicate. Asterisks indicate statistically signiﬁcant differences (*p b 0.05) c3.5. Cystamine induces AIF nuclear translocation in a cell-type
speciﬁc manner
AIF is a mitochondrial ﬂavoprotein that plays a major role in
caspase-independent cell death [28]. Confocal microscopic analyses re-
vealed that cystamine induced AIF nuclear translocation only in DU145
and HeLa cells, but not in MCF7 and A549 cells (Fig. 5a). Moreover,
cystamine-induced AIF nuclear translocation was completely blocked
by NAC (Fig. 5b). To further conﬁrm the causal role of AIF in
cystamine-induced cell death, we compared the cystamine cytotoxicity
in wild-type and AIF-downregulated cells. AIF knockdown by siRNAAIF localization in cystamine-treated cells. DU145, HeLa,MCF7 andA549 cellswere treated
gated goat anti-mouse IgG. AIF nuclear translocation was evaluated using confocal micros-
ntibodies and FITC-conjugated goat anti-mouse IgG in the presence of cystamine (500 μM)
h. HeLa cells were treatedwith AIF-speciﬁc siRNA. AIF protein levels and cell viability after
ely. The data represent themean values± standard deviations based on experiments that
ompared with control siRNA-treated cells.
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inverse relationship between AIF expression and cystamine cytotoxicity
(Fig. 5c). These results indicate that cystamine induces cell death via AIF
nuclear translocation.
We next tested the possibility that GSH depletion below a certain
level may trigger AIF nuclear translocation. In cystamine-treated
DU145 and HeLa cells, immunocytochemical staining demonstrated
that GSH-EE treatment prevented cystamine-induced AIF nuclear trans-
location (Fig. 6), indicating that GSH depletion is critical for triggering
AIF nuclear translocation.
3.6. Cystamine-induced AIF translocation is not associated with calpain I
and PARP-1
Calpain I and poly (ADP-ribose) polymerase-1 (PARP-1) are involved
in AIF nuclear translocation by various apoptogenic stimuli [28]. To as-
sess whether these enzymes are also required for cystamine-induced
AIF translocation, we treated DU145 and HeLa cells with the calpain
inhibitor ALLN or the PARP-1 inhibitor DPQ (3,4-dihydro-5-[4-(1-
piperidinyl)butoxy]-1(2H)-isoquinolinone), and we found that these
enzyme inhibitors had no effect on cystamine-induced cell death in
both cell lines (Fig. 7a, b), suggesting that GSH depletion might be a
new pathway for promoting AIF nuclear translocation.
3.7. Cysteamine induces AIF-mediated apoptosis in a rat model of
duodenal ulcer
We next sought to extend these results from cellular models to an
in vivo model of cysteamine toxicity. In rat, cysteamine is a well-
known chemical to induce perforating duodenal ulcer in the proximal
duodenum after 24–48 h of administration [20,34]. We tested whether
intragastric administration of cysteamine could induce apoptosis of du-
odenal epithelial cells by depleting GSH and triggering AIF nuclear
translocation. Female Sprague–Dawley rats received cysteamine (25
mg/100 g body weight) three times at 4 h intervals. Duodenal ulcer
was developed within 48 h in all animals receiving cysteamine. When
GSH levels were determined in the duodenal tissues, total GSH concen-
trationswere decreased after 10 hwhichwere restored after 24 h of cys-
teamine administration (Fig. 8a). Concurrently, immunoﬂuorescence
staining of AIF revealed that AIFwas translocated into the nucleus of du-
odenal epithelium after 24 h of cysteamine administration (Fig. 8b), in-
dicating that AIF translocation caused by GSH depletion may be a
relevant molecular mechanism for cysteamine-induced duodenal ulcer
in rat.Fig. 6. Cystamine-induced AIF translocation depends on intracellular GSH levels. DU145 and He
with anti-AIF antibodies and FITC-conjugated goat anti-mouse IgG. Scale bar: 50 μm.4. Discussion
In the present study, we investigated cystamine toxicity and
found that cystamine induced caspase-independent cell death in a
cell type-speciﬁc manner. Comparison between cystamine-sensitive
and -resistant cells demonstrated that cystamine-induced cell death is
caused by AIF nuclear translocation. Subsequent analyses identiﬁed the
decreased GSH levels as a triggering factor for AIF translocation. A causal
role of GSH depletion is demonstrated by the observations that GSH sup-
plementation completely preventedAIF nuclear translocation.Moreover,
these results from cellular models were veriﬁed in a rat model of
cysteamine-induced duodenal ulcer. Our data also demonstrated that
cystamine cytotoxicity is not associated with its ability to induce unfold-
ed protein response, to generate ROS, or to inhibit TG2 activity. Collec-
tively, our results indicate that AIF nuclear translocation induced by
GSH depletion is a critical molecular event in cystamine toxicity.
Cysteamine is an intracellular reduced form of cystamine and is
synthesized from pantetheine by membrane-anchored pantetheinase,
an enzyme encoded by the widely expressed vanin gene family. Cyste-
amine is catabolized to hypotaurine and taurine by cysteamine
dioxygenase [18,39]. The concentrations of cystamine and cysteamine
in brain and plasma are very low (under the detection limit) [40], and
the molecular mechanism of transport of cystamine and cysteamine
into cells has not been revealed yet. Although cysteamine is an
aminothiol that could act as an antioxidant scavenging hydroxyl radical,
hypochlorous acid and hydrogen peroxide [4], the physiological role of
cysteamine remains unknown because conﬂicting evidences of its role
in redox regulation have been reported. Administration of cystamine
showed rapid cleavage into two cysteamine molecules and an increase
of the cellular antioxidant L-cysteine in mouse model of Huntington's
disease [1,41] and GSH levels particularly in neuronal cells and tissues
inmouse [3,42]. On the other hand, pantetheinase-deﬁcientmice exhib-
ited higher GSH production, suggesting an inhibitory role of cysteamine
inGSH synthesis [6]. Consistentwith these results, our data demonstrat-
ed that cysteamine treatment suppresses cellular GSH production in rat
duodenal epithelial cells as well as in speciﬁc cell-lines, indicating that
intracellular GSH regulation is a critical determinant of cystamine
cytotoxicity. Cysteamine is currently used to treat patientswith nephro-
pathic cystinosis. Recently, cystamine or cysteamine demonstrated ben-
eﬁcial effects in mouse models of Huntington's disease [8], Parkinson's
disease [10], selenite-induced cataract formation [39] and bleomycin-
induced lung ﬁbrosis [43]. The results described here suggest that
these effects of cystamine should be carefully re-evaluated after long-
term administration.La cells were treatedwith GSH-EE (2.5 mM) and cystamine (500 μM) and immunostained
Fig. 7. Effect of inhibitors for calpain or poly (ADP-ribose) polymerase-1 (PARP-1) on cystamine cytotoxicity. (a, b) DU145 andHeLa cells were treatedwith cystamine (Cys, 500 μM) in the
presence of calpain inhibitor ALLN (0.1–10 μM, a) or PARP-1 inhibitor DPQ (0.01–60 μM, b) for 72 h. Cell viability was measured by MTT assay. Dimethyl sulfoxide (DMSO)-treated cells
were used as control for inhibitors. The data represent the mean values ± standard deviations based on experiments that were performed in triplicate.
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scriptional level, cellular GSH content is strictly regulated by GCS ex-
pression levels. GCS is a heterodimer that is composed of a catalytic
(GCSC) and modiﬁer subunit (GCSM). GCSC transcription is regulated
by TPA and an electrophile response element, which are activated by
AP-1 and Nrf2, respectively [21]. Cystamine treatment reportedly acti-
vated Nrf2 pathway both in cell culture and in brain tissue [42]. At the
enzyme level, GCSC activity is increased by GCSM in response to oxida-
tive insults, but is inhibited by GSH via negative feedback [44]. More-
over, GCSC is inhibited by cellular metabolite cysteamine through a
sulfhydryl–disulﬁde interchange reaction between GCSC and cyste-
amine in vitro and in vivo [2,6]. Thus, the decreased GCSC activity and
expression in cystamine-treated cells as demonstrated in this study
suggest that cystamine functions as a negative regulator to limit GSH
production, which modulates cellular responses to external stress.
Although NAC replenishes intracellular GSH by providing cysteine, the
protective effect of NAC in cystamine cytotoxicity is probably attributed
to a direct adduct formation and interference with cystamine, or
substitute for the functions of GSH through its sulfhydryl group. In addi-
tion, our data also suggest that aberrant regulation of GSH level maycontribute to the defective triggering of AIF nuclear translocation in
response to various apoptotic stimuli. Therefore, regulation of intracel-
lular GSH levels is an important point of control in AIF-mediated
caspase-independent cell death.
AIF is an oxidoreductase located in the mitochondrial inner mem-
branewhich is essential for maintenance of themitochondrial respirato-
ry chain complex I and redox status [45]. AIF also mediates caspase-
independent cell death in response to alkylating agents, excitotoxins,
hypoxia/ischemia and growth factor deprivation [28]. Our data demon-
strated that GSH depletion triggers AIF nuclear translocation even
in the absence of oxidative stress, indicating that GSH depletion is a
downstream signal linking apoptotic stimuli with AIF nuclear transloca-
tion, but is not a simple marker of oxidative stress in the caspase-
independent cell death. In support of this notion, increased export of cel-
lular GSHhas been observed in AIF-mediated cell death induced by treat-
ment with glutamate, N-methyl-D-aspartate, kainate, and hypoxia/
ischemia [46–48]. Moreover, our results also showed decreased total
GSH in the cysteamine-treated duodenal mucosal cells in rats. These ob-
servations suggest that increased GSH efﬂux likely contributes to GSH
depletion causing AIF-mediated cell death. Because GSH efﬂux is an
Fig. 8. Cysteamine induces AIF-mediated apoptosis through GSH depletion in a rat model of duodenal ulcer. (a) Total and reduced GSH levels in the proximal duodenal tissues after cys-
teamine administration. Duodenal ulcers were induced in female Sprague–Dawley rats by intragastric cysteamine administration. Three doses of cysteamine (25 mg/100 g body weight
each time)were given at 4 h intervals, and GSH levelswere estimated 10 and 24 h after theﬁrst dose of cysteamine. Asterisk indicates statistically signiﬁcant difference (*p b 0.05). (b) AIF
localization in cysteamine-treated rat duodenum. After cysteamine administration, duodenal tissues were immunostained with anti-AIF antibodies and FITC-conjugated goat anti-mouse
IgG, and nuclei were counter-stained with DAPI. Scale bar: 20 μm.
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such as multidrug resistance proteins, the organic anion transporter
and the glutamate/aspartate transporter might play an important role
in modulation of AIF-mediated cell death [49]. Thus, it will be of interest
to elucidate the role of GSH transporters in AIF translocation that is in-
duced by chemicals associated with cellular redox status and GSH level
alterations including As2O3, cladribine, granulysin, geldanamycin,
staurosporine, sulindac, camptothecin, hexaminolevulinate and DNA
alkylating agents [28]. Moreover, GSH depletion is also required for cas-
pase activation, apoptosome formation and cytosolic cytochrome c re-
lease, most likely through redox-based protein modiﬁcations such as
glutathionylation and nitrosylation [22]. Therefore, GSH depletion may
be involved in the regulation of caspase-independent and -dependent
apoptosis.
The Harlequin (Hq) mouse is a strain that harbors an AIF gene inser-
tion mutation resulting in an 80% reduction of AIF expression. Hqmiceexhibited protection from ischemia-induced brain damage, and primary
neuronal cells were resistant to hypoxia/ischemia-induced cell death
[50–52]. However, Hq mice paradoxically developed age-associated
cerebellum and retinal degeneration with increased lipid peroxide and
8-hydroxydeoxyguanine levels [22], and cultured cerebellar granule
cells from Hq mice were more sensitive to ROS-induced cell death
than those from wild-type mice [53]. Our results may provide a molec-
ular explanation for these contradictory phenotypes of Hq mice. We
demonstrated that AIF-mediated cell death occurred under GSH-
depleted conditions, suggesting that AIF functions as an eliminator of
cells with low GSH content. Therefore, AIF-knockdown cells could sur-
vive even in low GSH levels in which wild-type cells undergo cell
death, but these cells subsequently become dysfunctional due to the ac-
cumulation of oxidatively damaged molecule. Moreover, the defective
complex I function in AIF-knockdown cells may also contribute to in-
creased oxidative stress. Interestingly, AIF protein levels in the cortical
630 S.-Y. Cho et al. / Biochimica et Biophysica Acta 1853 (2015) 619–631area of normal human brains reportedly increased with aging, but was
lower in cortical brains from Alzheimer's disease patients compared
with age-matched controls [54], suggesting a role for AIF in the patho-
genesis of neurodegenerative disease. However, further studies would
be required to establish the cause-result relationship between AIF ex-
pression and neurodegeneration.
In summary, we demonstrated that cystamine-induced GSH deple-
tion caused cell death by triggering AIF nuclear translocation in cellular
and animal models. This is the ﬁrst report on themolecular mechanism
of cystamine toxicity and provides important implications for cystamine
in neurodegenerative disease therapeutics. In addition, our data indicate
that GSHmay play a role in the regulation of AIF-mediated cell death as
well as in the maintenance of redox homeostasis in response to oxida-
tive stress. These results may provide new insights into the pathophys-
iological role of cysteamine, GSH and AIF in various diseases.
Acknowledgement
This work was supported by grants from the National Research
Foundation of Korea (NRF-2010-0014684, 2010-0019472, and
2012R1A1A2005188) and the Korea Healthcare Technology R&D pro-
ject, Ministry of Health and Welfare (grant No. A100190). S.Y.C., J.H.L.
and H.J.K. were supported by the second phase of the Brain Korea 21
Program (5262-20140100).
References
[1] J.H. Fox, D.S. Barber, B. Singh, B. Zucker, M.K. Swindell, F. Norﬂus, R. Buzescu, R.
Chopra, R.J. Ferrante, A. Kazantsev, S.M. Hersch, Cystamine increases L-cysteine
levels in Huntington's disease transgenic mouse brain and in a PC12 model of
polyglutamine aggregation, J. Neurochem. 91 (2004) 413–422.
[2] O.W. Grifﬁth, A. Larsson, A. Meister, Inhibition of gamma-glutamylcysteine synthe-
tase by cystamine: an approach to a therapy of 5-oxoprolinuria (pyroglutamic
aciduria), Biochem. Biophys. Res. Commun. 79 (1977) 919–925.
[3] M. Lesort, M. Lee, J. Tucholski, G.V. Johnson, Cystamine inhibits caspase activity. Im-
plications for the treatment of polyglutamine disorders, J. Biol. Chem. 278 (2003)
3825–3830.
[4] O.I. Aruoma, B. Halliwell, B.M. Hoey, J. Butler, The antioxidant action of taurine,
hypotaurine and their metabolic precursors, Biochem. J. 256 (1988) 251–255.
[5] T.M. Jeitner, E.J. Delikatny, J. Ahlqvist, H. Capper, A.J. Cooper, Mechanism for the
inhibition of transglutaminase 2 by cystamine, Biochem. Pharmacol. 69 (2005)
961–970.
[6] F. Martin, M.F. Penet, F. Malergue, H. Lepidi, A. Dessein, F. Galland, M. de Reggi, P.
Naquet, B. Gharib, Vanin-1(−/−) mice show decreased NSAID- and Schistosoma-
induced intestinal inﬂammation associated with higher glutathione stores, J. Clin.
Invest. 113 (2004) 591–597.
[7] A. Dedeoglu, J.K. Kubilus, T.M. Jeitner, S.A. Matson, M. Bogdanov, N.W. Kowall, W.R.
Matson, A.J. Cooper, R.R. Ratan, M.F. Beal, S.M. Hersch, R.J. Ferrante, Therapeutic ef-
fects of cystamine in a murine model of Huntington's disease, J. Neurosci. 22 (2002)
8942–8950.
[8] M.V. Karpuj, M.W. Becher, J.E. Springer, D. Chabas, S. Youssef, R. Pedotti, D. Mitchell,
L. Steinman, Prolonged survival and decreased abnormal movements in transgenic
model of Huntington disease, with administration of the transglutaminase inhibitor
cystamine, Nat. Med. 8 (2002) 143–149.
[9] E.C. Stack, J.L. Ferro, J. Kim, S.J. Del Signore, S. Goodrich, S. Matson, B.B. Hunt, K.
Cormier, K. Smith,W.R. Matson, H. Ryu, R.J. Ferrante, Therapeutic attenuation of mi-
tochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's
disease, Biochim. Biophys. Acta 1782 (2008) 151–162.
[10] M.E. Tremblay, M. Saint-Pierre, E. Bourhis, D. Levesque, C. Rouillard, F. Cicchetti,
Neuroprotective effects of cystamine in aged parkinsonian mice, Neurobiol. Aging
27 (2006) 862–870.
[11] S. Igarashi, R. Koide, T. Shimohata, M. Yamada, Y. Hayashi, H. Takano, H. Date, M.
Oyake, T. Sato, A. Sato, S. Egawa, T. Ikeuchi, H. Tanaka, R. Nakano, K. Tanaka, I.
Hozumi, T. Inuzuka, H. Takahashi, S. Tsuji, Suppression of aggregate formation and
apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA pro-
tein with an expanded polyglutamine stretch, Nat. Genet. 18 (1998) 111–117.
[12] T.C. Hsu, Y.C. Chen, W.X. Lai, S.Y. Chiang, C.Y. Huang, B.S. Tzang, Beneﬁcial effects of
treatment with cystamine on brain in NZB/WF1 mice, Eur. J. Pharmacol. 591 (2008)
307–314.
[13] R. Dubinsky, C. Gray, CYTE-I-HD: phase I dose ﬁnding and tolerability study of cys-
teamine (Cystagon) in Huntington's disease, Mov. Disord. 21 (2006) 530–533.
[14] R. Ientile, A. Campisi, G. Raciti, D. Caccamo, M. Curro, G. Cannavo, G. Li Volti, S.
Macaione, A. Vanella, Cystamine inhibits transglutaminase and caspase-3 cleavage
in glutamate-exposed astroglial cells, J. Neurosci. Res. 74 (2003) 52–59.
[15] M. Borrell-Pages, J.M. Canals, F.P. Cordelieres, J.A. Parker, J.R. Pineda, G. Grange, E.A.
Bryson, M. Guillermier, E. Hirsch, P. Hantraye, M.E. Cheetham, C. Neri, J. Alberch, E.
Brouillet, F. Saudou, S. Humbert, Cystamine and cysteamine increase brain levelsof BDNF in Huntington disease via HSJ1b and transglutaminase, J. Clin. Invest. 116
(2006) 1410–1424.
[16] L. Di Leandro, B. Maras, M.E. Schinina, S. Dupre, I. Koutris, F.M. Martin, P. Naquet, F.
Galland, G. Pitari, Cystamine restores GSTA3 levels in Vanin-1 null mice, Free Radic.
Biol. Med. 44 (2008) 1088–1096.
[17] R.V. Lebo, N.M. Kredich, Inactivation of human gamma-glutamylcysteine synthetase
by cystamine. Demonstration and quantiﬁcation of enzyme–ligand complexes,
J. Biol. Chem. 253 (1978) 2615–2623.
[18] G. Pitari, F. Malergue, F. Martin, J.M. Philippe, M.T. Massucci, C. Chabret, B. Maras, S.
Dupre, P. Naquet, F. Galland, Pantetheinase activity of membrane-bound Vanin-1:
lack of free cysteamine in tissues of Vanin-1 deﬁcient mice, FEBS Lett. 483 (2000)
149–154.
[19] C. Berruyer, F.M. Martin, R. Castellano, A. Macone, F. Malergue, S. Garrido-Urbani, V.
Millet, J. Imbert, S. Dupre, G. Pitari, P. Naquet, F. Galland, Vanin-1−/−mice exhibit a
glutathione-mediated tissue resistance to oxidative stress, Mol. Cell. Biol. 24 (2004)
7214–7224.
[20] S. Szabo, X. Deng, T. Khomenko, L. Chen, G. Tolstanova, K. Osapay, Z. Sandor, X.
Xiong, New molecular mechanisms of duodenal ulceration, Ann. N. Y. Acad. Sci.
1113 (2007) 238–255.
[21] H.J. Forman, H. Zhang, A. Rinna, Glutathione: overview of its protective roles,
measurement, and biosynthesis, Mol. Aspects Med. 30 (2009) 1–12.
[22] R. Franco, J.A. Cidlowski, Apoptosis and glutathione: beyond an antioxidant, Cell
Death Differ. 16 (2009) 1303–1314.
[23] T.P. Dalton, Y. Chen, S.N. Schneider, D.W. Nebert, H.G. Shertzer, Genetically altered
mice to evaluate glutathione homeostasis in health and disease, Free Radic. Biol.
Med. 37 (2004) 1511–1526.
[24] J.S. Armstrong, K.K. Steinauer, B. Hornung, J.M. Irish, P. Lecane, G.W. Birrell, D.M.
Peehl, S.J. Knox, Role of glutathione depletion and reactive oxygen species genera-
tion in apoptotic signaling in a human B lymphoma cell line, Cell Death Differ. 9
(2002) 252–263.
[25] C. Friesen, Y. Kiess, K.M. Debatin, A critical role of glutathione in determining apo-
ptosis sensitivity and resistance in leukemia cells, Cell Death Differ. 11 (Suppl. 1)
(2004) S73–S85.
[26] R. Franco, M.I. Panayiotidis, J.A. Cidlowski, Glutathione depletion is necessary for ap-
optosis in lymphoid cells independent of reactive oxygen species formation, J. Biol.
Chem. 282 (2007) 30452–30465.
[27] N. Joza, J.A. Pospisilik, E. Hangen, T. Hanada, N. Modjtahedi, J.M. Penninger, G.
Kroemer, AIF: not just an apoptosis-inducing factor, Ann. N. Y. Acad. Sci. 1171
(2009) 2–11.
[28] H.K. Lorenzo, S.A. Susin, Therapeutic potential of AIF-mediated caspase-independent
programmed cell death, Drug Resist. Updat. 10 (2007) 235–255.
[29] M. Baritaud, H. Boujrad, H.K. Lorenzo, S. Krantic, S.A. Susin, Histone H2AX: the miss-
ing link in AIF-mediated caspase-independent programmed necrosis, Cell Cycle 9
(2010) 3166–3173.
[30] E. Daugas, S.A. Susin, N. Zamzami, K.F. Ferri, T. Irinopoulou, N. Larochette, M.C.
Prevost, B. Leber, D. Andrews, J. Penninger, G. Kroemer,Mitochondrio-nuclear trans-
location of AIF in apoptosis and necrosis, FASEB J. 14 (2000) 729–739.
[31] S.Y. Cho, J.H. Lee, H.D. Bae, E.M. Jeong, G.Y. Jang, C.W. Kim, D.M. Shin, J.H. Jeon, I.G.
Kim, Transglutaminase 2 inhibits apoptosis induced by calcium-overload through
down-regulation of Bax, Exp. Mol. Med. 42 (2010) 639–650.
[32] J.J. Gu, K. Gathy, L. Santiago, E. Chen, M. Huang, L.M. Graves, B.S. Mitchell, Induction
of apoptosis in IL-3-dependent hematopoietic cell lines by guanine nucleotide de-
pletion, Blood 101 (2003) 4958–4965.
[33] J.H. Jeon, C.W. Kim, D.M. Shin, K. Kim, S.Y. Cho, J.C. Kwon, K.H. Choi, H.S. Kang, I.G.
Kim, Differential incorporation of biotinylated polyamines by transglutaminase 2,
FEBS Lett. 534 (2003) 180–184.
[34] T. Khomenko, J. Kolodney, J.T. Pinto, G.D. McLaren, X. Deng, L. Chen, G. Tolstanova, B.
Paunovic, B.F. Krasnikov, N. Hoa, A.J. Cooper, S. Szabo, Newmechanistic explanation
for the localization of ulcers in the rat duodenum: role of iron and selective uptake
of cysteamine, Arch. Biochem. Biophys. 525 (2012) 60–70.
[35] M. Csala, E. Margittai, G. Banhegyi, Redox control of endoplasmic reticulum function,
Antioxid. Redox Signal. 13 (2010) 77–108.
[36] T.M. Jeitner, D.A. Lawrence, Mechanisms for the cytotoxicity of cysteamine, Toxicol.
Sci. 63 (2001) 57–64.
[37] G.Y. Jang, J.H. Jeon, S.Y. Cho, D.M. Shin, C.W. Kim, E.M. Jeong, H.C. Bae, T.W. Kim, S.H.
Lee, Y. Choi, D.S. Lee, S.C. Park, I.G. Kim, Transglutaminase 2 suppresses apoptosis by
modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells, Oncogene 29
(2010) 356–367.
[38] L. Galluzzi, I. Vitale, J.M. Abrams, E.S. Alnemri, E.H. Baehrecke, M.V. Blagosklonny,
T.M. Dawson, V.L. Dawson, W.S. El-Deiry, S. Fulda, E. Gottlieb, D.R. Green, M.O.
Hengartner, O. Kepp, R.A. Knight, S. Kumar, S.A. Lipton, X. Lu, F. Madeo, W.
Malorni, P. Mehlen, G. Nunez, M.E. Peter, M. Piacentini, D.C. Rubinsztein, Y. Shi,
H.U. Simon, P. Vandenabeele, E. White, J. Yuan, B. Zhivotovsky, G. Melino, G.
Kroemer, Molecular deﬁnitions of cell death subroutines: recommendations of the
Nomenclature Committee on Cell Death 2012, Cell Death Differ. 19 (2012) 107–120.
[39] S.M. Lee, E.M. Jeong, J. Jeong, D.M. Shin, H.J. Lee, H.J. Kim, J. Lim, J.H. Lee, S.Y. Cho,
M.K. Kim, W.R. Wee, J.H. Lee, I.G. Kim, Cysteamine prevents the development of
lens opacity in a rat model of selenite-induced cataract, Invest. Ophthalmol. Vis.
Sci. 53 (2012) 1452–1459.
[40] J.T. Pinto, J.M. Van Raamsdonk, B.R. Leavitt, M.R. Hayden, T.M. Jeitner, H.T. Thaler, B.F.
Krasnikov, A.J. Cooper, Treatment of YAC128 mice and their wild-type littermates
with cystamine does not lead to its accumulation in plasma or brain: implications
for the treatment of Huntington disease, J. Neurochem. 94 (2005) 1087–1101.
[41] M. Bousquet, C. Gibrat, M. Ouellet, C. Rouillard, F. Calon, F. Cicchetti, Cystamine me-
tabolism and brain transport properties: clinical implications for neurodegenerative
diseases, J. Neurochem. 114 (2010) 1651–1658.
631S.-Y. Cho et al. / Biochimica et Biophysica Acta 1853 (2015) 619–631[42] M.J. Calkins, J.A. Townsend, D.A. Johnson, J.A. Johnson, Cystamine protects from
3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated
transcription, Exp. Neurol. 224 (2010) 307–317.
[43] K. Oh, H.B. Park, O.J. Byoun, D.M. Shin, E.M. Jeong, Y.W. Kim, Y.S. Kim, G. Melino, I.G.
Kim, D.S. Lee, Epithelial transglutaminase 2 is needed for T cell interleukin-17 pro-
duction and subsequent pulmonary inﬂammation and ﬁbrosis in bleomycin-
treated mice, J. Exp. Med. 208 (2011) 1707–1719.
[44] M. Tosic, J. Ott, S. Barral, P. Bovet, P. Deppen, F. Gheorghita, M.L. Matthey, J. Parnas,
M. Preisig, M. Saraga, A. Solida, S. Timm, A.G. Wang, T. Werge, M. Cuenod, K.Q. Do,
Schizophrenia and oxidative stress: glutamate cysteine ligase modiﬁer as a suscep-
tibility gene, Am. J. Hum. Genet. 79 (2006) 586–592.
[45] N. Vahsen, C. Cande, J.J. Briere, P. Benit, N. Joza, N. Larochette, P.G. Mastroberardino,
M.O. Pequignot, N. Casares, V. Lazar, O. Feraud, N. Debili, S. Wissing, S. Engelhardt, F.
Madeo, M. Piacentini, J.M. Penninger, H. Schagger, P. Rustin, G. Kroemer, AIF deﬁ-
ciency compromises oxidative phosphorylation, EMBO J. 23 (2004) 4679–4689.
[46] T.B. Garcia, K.R. Oliveira, J.L. do Nascimento, M.E. Crespo-Lopez, D.L. Picanco-Diniz,
T.C. Mota, A.M. Herculano, Glutamate induces glutathione efﬂux mediated by
glutamate/aspartate transporter in retinal cell cultures, Neurochem. Res. 36
(2011) 412–418.
[47] O. Orwar, X. Li, P. Andine, C.M. Bergstrom, H. Hagberg, S. Folestad, M. Sandberg,
Increased intra- and extracellular concentrations of gamma-glutamylglutamate
and related dipeptides in the ischemic rat striatum: involvement of glutamyl
transpeptidase, J. Neurochem. 63 (1994) 1371–1376.[48] C. Wallin, S.G. Weber, M. Sandberg, Glutathione efﬂux induced by NMDA and
kainate: implications in neurotoxicity? J. Neurochem. 73 (1999) 1566–1572.
[49] R. Franco, J.A. Cidlowski, Glutathione efﬂux and cell death, Antioxid. Redox Signal.
17 (2012) 1694–1713.
[50] G. Cao, J. Xing, X. Xiao, A.K. Liou, Y. Gao, X.M. Yin, R.S. Clark, S.H. Graham, J. Chen,
Critical role of calpain I in mitochondrial release of apoptosis-inducing factor in
ischemic neuronal injury, J. Neurosci. 27 (2007) 9278–9293.
[51] C. Culmsee, C. Zhu, S. Landshamer, B. Becattini, E. Wagner, M. Pellecchia, K.
Blomgren, N. Plesnila, Apoptosis-inducing factor triggered by poly(ADP-ribose) po-
lymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation
and focal cerebral ischemia, J. Neurosci. 25 (2005) 10262–10272.
[52] C. Zhu, X. Wang, Z. Huang, L. Qiu, F. Xu, N. Vahsen, M. Nilsson, P.S. Eriksson, H.
Hagberg, C. Culmsee, N. Plesnila, G. Kroemer, K. Blomgren, Apoptosis-inducing
factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia–
ischemia, Cell Death Differ. 14 (2007) 775–784.
[53] V. El Ghouzzi, Z. Csaba, P. Olivier, B. Lelouvier, L. Schwendimann, P. Dournaud, C.
Verney, P. Rustin, P. Gressens, Apoptosis-inducing factor deﬁciency induces early
mitochondrial degeneration in brain followed by progressive multifocal neuropa-
thology, J. Neuropathol. Exp. Neurol. 66 (2007) 838–847.
[54] S. Reix, N. Mechawar, S.A. Susin, R. Quirion, S. Krantic, Expression of cortical and hip-
pocampal apoptosis-inducing factor (AIF) in aging and Alzheimer's disease,
Neurobiol. Aging 28 (2007) 351–356.
